CB2 receptor-mediated antihyperalgesia: possible direct involvement of neural mechanisms.
about
The endocannabinoid system, cannabinoids, and painA cannabinoid 2 receptor agonist attenuates bone cancer-induced pain and bone lossTargeting the endocannabinoid system with cannabinoid receptor agonists: pharmacological strategies and therapeutic possibilitiesCrucial role of CB(2) cannabinoid receptor in the regulation of central immune responses during neuropathic painThe diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarinPathological and protective roles of glia in chronic painSpecies-specific in vitro pharmacological effects of the cannabinoid receptor 2 (CB2) selective ligand AM1241 and its resolved enantiomersActions of N-arachidonyl-glycine in a rat inflammatory pain modelExpression of functional cannabinoid CB2 receptor in VTA dopamine neurons in ratsInternational Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB₁ and CB₂Targeting cannabinoid agonists for inflammatory and neuropathic painContributions of academic laboratories to the discovery and development of chemical biology toolsBrain neuronal CB2 cannabinoid receptors in drug abuse and depression: from mice to human subjectsFunctional expression of brain neuronal CB2 cannabinoid receptors are involved in the effects of drugs of abuse and in depressionCannabinoid CB2 receptors in the enteric nervous system modulate gastrointestinal contractility in lipopolysaccharide-treated ratsPeripheral gating of pain signals by endogenous lipid mediators.Brain CB₂ Receptors: Implications for Neuropsychiatric Disorders.Antinociceptive effects of racemic AM1241 and its chirally synthesized enantiomers: lack of dependence upon opioid receptor activation.Cannabinoid CB1 receptor facilitation of substance P release in the rat spinal cord, measured as neurokinin 1 receptor internalization.Cannabinoids as pharmacotherapies for neuropathic pain: from the bench to the bedsideCB2: a cannabinoid receptor with an identity crisisThe endocannabinoid system as a target for the treatment of neurodegenerative disease.Adolescent cannabis use and psychosis: epidemiology and neurodevelopmental modelsTreatment with a cannabinoid receptor 2 agonist decreases severity of established cystitisBrain cannabinoid CB₂ receptors modulate cocaine's actions in miceValidating Antibodies to the Cannabinoid CB2 Receptor: Antibody Sensitivity Is Not Evidence of Antibody Specificity.Modulation of pain transmission by G-protein-coupled receptors.Dimerization with cannabinoid receptors allosterically modulates delta opioid receptor activity during neuropathic pain.Chronic blockade of cannabinoid CB2 receptors induces anxiolytic-like actions associated with alterations in GABA(A) receptors.Selective activation of cannabinoid CB2 receptors suppresses neuropathic nociception induced by treatment with the chemotherapeutic agent paclitaxel in ratsPharmacological characterization of AM1710, a putative cannabinoid CB2 agonist from the cannabilactone class: antinociception without central nervous system side-effectsMinocycline treatment inhibits microglial activation and alters spinal levels of endocannabinoids in a rat model of neuropathic pain.Molecular mechanisms involved in the antitumor activity of cannabinoids on gliomas: role for oxidative stress.Design and evaluation of a novel fluorescent CB2 ligand as probe for receptor visualization in immune cellsPromising cannabinoid-based therapies for Parkinson's disease: motor symptoms to neuroprotection2,3-Dihydro-1-benzofuran derivatives as a series of potent selective cannabinoid receptor 2 agonists: design, synthesis, and binding mode prediction through ligand-steered modeling.Attenuation of persistent pain-related behavior by fatty acid amide hydrolase (FAAH) inhibitors in a rat model of HIV sensory neuropathy.Activation of cannabinoid CB2 receptors reduces hyperalgesia in an experimental autoimmune encephalomyelitis mouse model of multiple sclerosis.Prevention of paclitaxel-induced neuropathy through activation of the central cannabinoid type 2 receptor system.The fatty acid amide hydrolase (FAAH) inhibitor PF-3845 acts in the nervous system to reverse LPS-induced tactile allodynia in mice.
P2860
Q24601890-D95D36F4-1989-4C66-A0F9-B42985155D63Q24615787-853D089C-A940-4BAD-B64B-13B303636F1BQ24623282-3FECF265-28EC-477F-B47B-1EC38B2CEBEAQ24634161-0991F505-DE87-428B-A95D-C4B53D1F96DBQ24643876-81BFCEBC-E000-4A35-9E3F-A4AAAD842E47Q24646738-8E944D8F-82FC-45B1-8121-45F38E977ED8Q24673335-08F17B67-B61E-4729-96C2-12DCA9D08A90Q27498684-A2BDC402-F697-4B25-8BB1-5CCA2776DA2FQ28272826-23F2A630-EAA8-4ED3-A06D-2C0560BCCD7CQ28298445-D1E5D932-7B2A-4DA7-BA12-09B5609C17D2Q28307619-8583BBD7-639A-4286-ABB4-156E62C3E596Q28389188-E3B95295-E417-4E87-BBB5-FBAE7F833543Q28472191-BA47D4EB-4ACD-41A7-A378-D7F17BB2916CQ28566269-1DFA92CD-B6C6-4C68-B8EC-EB07A3E30757Q28568772-9BB38988-AB23-420A-962A-04A674D414D1Q33608432-11FC6C8F-F247-4ACB-94C9-4EB31734B234Q33664105-C63E998E-0AF0-4E4E-9661-5CCE8A0DF070Q33749455-FB67EA9B-BFCF-4ABA-A15C-390EB9C9DF95Q33803774-E70A434B-A4FF-4058-A692-CC2344E02640Q34019573-27534FC4-A6C4-4DA0-9949-67EE2F15BE20Q34098185-15BFAE4F-0D31-4C38-9351-BA7013D5320FQ34098196-29EF270C-4BCC-44EF-9E66-5FE7F383BA0EQ34098209-EA6E3CEC-973F-4E04-BC7E-2A40F2CF38A7Q34176058-3BCAEE69-E6A5-4437-BEF4-1D165C4231EFQ34203193-E5FAFD9E-FACB-4E1B-9EC1-7CA102EF31FEQ34241636-7ADD6F3E-5D82-4482-A5E6-94BFC63E5667Q34247711-29C437AA-30FC-48FE-9DF9-81D7A95C161BQ34524896-BDA7493A-E596-4E77-B391-BD176C6D0BFEQ34631608-3EB28F6E-D65C-4CF3-8742-A9B13A336B38Q34802605-2AD907E2-937D-4BD7-B422-66CA74682FBDQ34946680-41D3C71F-E1D1-495D-9D7F-F03A0C9853DDQ34990120-16593E03-E637-471F-AE5D-D258DA5E376EQ35054642-BEF36D40-02D8-4F78-B3C6-9102DFADA346Q35209538-4C37D58E-71D9-4011-8BBE-8B608C1CCC49Q35499568-08E015B4-75C4-4019-9B0D-29399CC8B89DQ35685828-582E25FC-F8E3-43E8-A6F0-209BBDDBF882Q35689152-B606560C-E1A8-49DC-BBE7-837204B3D406Q35731427-88FE400F-FD26-4E0E-96C7-CFAB15B53062Q35907148-B1E16FB3-9E45-4889-B9A4-C067C8001A12Q36176531-021E693F-413C-4F49-BF18-2F4B6D3098F3
P2860
CB2 receptor-mediated antihyperalgesia: possible direct involvement of neural mechanisms.
description
2006 nî lūn-bûn
@nan
2006 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի մարտին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
CB2 receptor-mediated antihyperalgesia: possible direct involvement of neural mechanisms.
@ast
CB2 receptor-mediated antihyperalgesia: possible direct involvement of neural mechanisms.
@en
CB2 receptor-mediated antihyperalgesia: possible direct involvement of neural mechanisms.
@nl
type
label
CB2 receptor-mediated antihyperalgesia: possible direct involvement of neural mechanisms.
@ast
CB2 receptor-mediated antihyperalgesia: possible direct involvement of neural mechanisms.
@en
CB2 receptor-mediated antihyperalgesia: possible direct involvement of neural mechanisms.
@nl
prefLabel
CB2 receptor-mediated antihyperalgesia: possible direct involvement of neural mechanisms.
@ast
CB2 receptor-mediated antihyperalgesia: possible direct involvement of neural mechanisms.
@en
CB2 receptor-mediated antihyperalgesia: possible direct involvement of neural mechanisms.
@nl
P2093
P1476
CB2 receptor-mediated antihyperalgesia: possible direct involvement of neural mechanisms
@en
P2093
Beltramo M
Bernardini N
Campanella M
Fredduzzi S
Nicolussi E
Reggiani A
P304
P356
10.1111/J.1460-9568.2006.04684.X
P407
P577
2006-03-01T00:00:00Z